ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 249 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q1 2021. The put-call ratio across all filers is 0.69 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,336,313 | +2.8% | 245,195 | +26.6% | 0.01% | +16.7% |
| Q2 2023 | $1,299,948 | -56.3% | 193,733 | -42.4% | 0.01% | -60.0% |
| Q1 2023 | $2,971,887 | -4.6% | 336,567 | -17.4% | 0.02% | -11.8% |
| Q4 2022 | $3,114,324 | +45.0% | 407,634 | +35.1% | 0.02% | +41.7% |
| Q3 2022 | $2,148,000 | +23.4% | 301,754 | +40.2% | 0.01% | +33.3% |
| Q2 2022 | $1,741,000 | +48.5% | 215,258 | +154.9% | 0.01% | +28.6% |
| Q1 2022 | $1,172,000 | +32.3% | 84,456 | +167.3% | 0.01% | +40.0% |
| Q4 2021 | $886,000 | +266.1% | 31,593 | +343.8% | 0.01% | +150.0% |
| Q3 2021 | $242,000 | -94.5% | 7,118 | -93.4% | 0.00% | -93.5% |
| Q2 2021 | $4,412,000 | -18.1% | 107,977 | -19.3% | 0.03% | -20.5% |
| Q1 2021 | $5,387,000 | -59.2% | 133,794 | -40.1% | 0.04% | -64.9% |
| Q4 2020 | $13,206,000 | +172.9% | 223,339 | +124.5% | 0.11% | +177.5% |
| Q3 2020 | $4,839,000 | +356.5% | 99,503 | +354.4% | 0.04% | +233.3% |
| Q2 2020 | $1,060,000 | – | 21,900 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,377,665 | $12,958,274 | 12.23% |
| Eagle Health Investments LP | 1,214,860 | $6,620,987 | 1.46% |
| Matrix Capital Management Company, LP | 11,572,590 | $63,070,616 | 0.76% |
| Aristotle Atlantic Partners, LLC | 3,058,206 | $16,667,223 | 0.67% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $163,465,709 | 0.66% |
| Pier Capital, LLC | 719,067 | $3,918,915 | 0.63% |
| DDD Partners, LLC | 783,697 | $3,385,571 | 0.49% |
| ARK Investment Management | 11,509,308 | $62,725,728 | 0.48% |
| Nikko Asset Management Americas, Inc. | 6,570,939 | $35,680,199 | 0.43% |
| Triatomic Management LP | 102,889 | $560,745 | 0.39% |